Related Experiment Video
Updated: May 15, 2025

A Reporter Based Cellular Assay for Monitoring Splicing Efficiency
Published on: September 15, 2021
U2AF1 mutations rescue deleterious exon skipping induced by KRAS mutations
David M Walter1,2,3, Katherine Cho1,2, Smruthy Sivakumar4
1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
Abstract:
The mechanisms by which somatic mutations of splicing factors, such as U2AF1S34F in lung adenocarcinoma, contribute to cancer pathogenesis are not well understood. Here, we used prime editing to modify the endogenous U2AF1 gene in lung adenocarcinoma cells and assessed the resulting impact on alternative splicing. These analyses identified KRAS as a key target modulated by U2AF1S34F. One specific KRAS mutation, G12S, generates a cryptic U2AF1 binding site that leads to skipping of KRAS exon 2 and generation of a non-functional KRAS transcript. Expression of the U2AF1S34F mutant reverts this exon skipping and restores KRAS function. Analysis of cancer genomes reveals that U2AF1S34F mutations are enriched in KRASG12S-mutant lung adenocarcinomas. A comprehensive analysis of splicing factor/oncogene mutation co-occurrence in cancer genomes also revealed significant co-enrichment of KRASQ61R and U2AF1I24T mutations. Experimentally, KRASQ61R mutation leads to KRAS exon 3 skipping, which in turn can be rescued by the expression of U2AF1I24T. Our findings provide evidence that splicing factor mutations can rescue splicing defects caused by oncogenic mutations. More broadly, they demonstrate a dynamic process of cascading selection where mutational events are positively selected in cancer genomes as a consequence of earlier mutations.
Insights
Splicing factor mutations in U2AF1 can rescue splicing defects caused by KRAS mutations in lung cancer. These findings reveal a cascading selection process in cancer genome evolution.
Area of Science:
- Molecular Biology
- Cancer Genomics
- Splicing Factor Function
Background:
- Mechanisms linking splicing factor mutations (e.g., U2AF1S34F) to lung adenocarcinoma pathogenesis remain unclear.
- Splicing alterations are increasingly recognized as drivers of cancer development.
Purpose of the Study:
- To investigate the functional impact of U2AF1 mutations on alternative splicing in lung adenocarcinoma.
- To identify key oncogenic targets modulated by splicing factor mutations.
Main Methods:
- Utilized prime editing to engineer endogenous U2AF1 mutations in lung adenocarcinoma cells.
- Performed alternative splicing analyses to assess transcriptomic changes.
- Analyzed cancer genome and clinical patient data for mutation co-occurrence and survival correlations.
Main Results:
- Identified KRAS as a direct target of U2AF1S34F, with U2AF1S34F rescuing KRAS exon 2 skipping caused by KRASG12S.
- Found enrichment of U2AF1S34F mutations in KRASG12S-mutant lung adenocarcinomas.
- Demonstrated that U2AF1I24T can rescue KRAS exon 3 skipping induced by KRASQ61R, with both U2AF1 mutations occurring secondary to KRAS mutations and associated with poorer survival.
Conclusions:
- Splicing factor mutations can act as suppressors of splicing defects introduced by oncogenic mutations, particularly in KRAS.
- These findings highlight a cascading selection mechanism in cancer evolution where secondary mutations rescue the functional impact of primary oncogenic events.
- U2AF1 mutations in lung adenocarcinoma may represent a compensatory response to KRAS oncogene activation.
Related Concept Videos
Alternative RNA Splicing
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
Nucleotide Excision Repair
The Ras Gene
Ras is a...
Exon Recombination
Exon shuffling follows “splice frame rules.” Each exon...
Nonsense-mediated mRNA Decay
Usually, Upf3 binds to an Exon Junction Complex (EJC) at mRNA splice sites. If a ribosome fully translates the mRNA,...
RNA Editing

